Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

National Institutes of Health. Financial Burden of Cancer Care [Internet]. 2024 [cited 2024 Mar 3]. https://progressreport.cancer.gov/after/economic_burden.

Orrantia-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE, Gómez-Valles FO, Ramírez-Valdespino CA. Subtypes of Breast Cancer. In: Mayrovitz HN, editor. Breast cancer. Brisbane (AU): Exon Publications; 2022. http://www.ncbi.nlm.nih.gov/books/NBK583808/.

NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) Breast Cancer Version 1.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. [cited 2024 Feb 17].

Turner N, Dent RA, O’Shaughnessy J, Kim S-B, Isakoff SJ, Barrios C, et al. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2022;191:565–76.

Article  CAS  PubMed  Google Scholar 

Mittal A, Molto Valiente C, Tamimi F, Schlam I, Sammons S, Tolaney SM, et al. Filling the gap after CDK4/6 inhibitors: novel endocrine and biologic treatment options for metastatic hormone receptor positive breast cancer. Cancers. 2023;15:2015.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med. 2012;366:520–9.

Article  CAS  PubMed  Google Scholar 

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380:1929–40.

Article  PubMed  Google Scholar 

Chen Z, Zheng Y, Cao W, Zhang Y, Zhao Z, Wang G, et al. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: a retrospective study. Cancer Med. 2019;8:5544–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim ST, Lee J, Park SH, Park JO, Park YS, Kang WK, et al. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer. 2017;17:211.

Article  PubMed  PubMed Central  Google Scholar 

Vernieri C, Corti F, Nichetti F, Ligorio F, Manglaviti S, Zattarin E, et al. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. Breast Cancer Res. 2020;22:33.

Article  PubMed  PubMed Central  Google Scholar 

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Moreno HLG, et al. Capivasertib in hormone receptor–positive advanced breast cancer. N Engl J Med. 2023;388:2058–70. https://doi.org/10.1056/NEJMoa2214131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drugs.com. Truqap prices, coupons, copay cards & patient assistance [Internet]. [cited 2024 Mar 3]. https://www.drugs.com/price-guide/truqap.

Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule [Internet]. 2023 [cited 2024 Mar 9]. https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs.

US Food and Drug Administration. FDA approves capivasertib with fulvestrant for breast cancer [Internet]. 2024 [cited 2024 Jun 12]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer.

TRUQAPTM (capivasertib) tablets, for oral use [Internet]. 2023 [cited 2024 May 13]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf.

Mamiya H, Tahara RK, Tolaney SM, Choudhry NK, Najafzadeh M. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. Ann Oncol. 2017;28:1825–31.

Article  CAS  PubMed  Google Scholar 

André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2—negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32:208–17.

Article  PubMed  Google Scholar 

Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9.

Article  PubMed  PubMed Central  Google Scholar 

Handorf EA, Beck JR, Correa A, Ramamurthy C, Geynisman DM. Cost-effectiveness analysis for therapy sequence in advanced cancer: a microsimulation approach with application to metastatic prostate cancer. Med Decis Making. 2023;43:949–60. https://doi.org/10.1177/0272989X231201621.

Smare C, Lakhdari K, Doan J, Posnett J, Johal S. Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. Pharmacoeconomics. 2020;38(1):97–108.

National Center for Health Statistics. US Life Tables 2019. [Internet]. 2022 [cited 2024 Jun 12] https://stacks.cdc.gov/view/cdc/113096.

Wu W, Lin H, Cai J, Sun H, Liu J, Hu C, et al. Is Alpelisib plus fulvestrant cost-effective for treating PIK3CA-mutation, HR+/HER2− advanced breast cancer in the USA? Clin Drug Investig. 2023;43(12):939–48. https://doi.org/10.1007/s40261-023-01325-z.

Mistry R, May JR, Suri G, Young K, Brixner D, Oderda G, et al. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer: a U.S. payer perspective. J Manag Care Spec Pharm. 2018;24:514–23. https://doi.org/10.18553/jmcp.2018.24.6.514.

Article  PubMed  Google Scholar 

Buehler AM, Castilho G, Dionne P-A, Stefani S. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective. Ther Adv Med Oncol. 2021;13:17588359211000592. https://doi.org/10.1177/17588359211000593. 

Article  CAS  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Hart L, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386:942–50. https://doi.org/10.1056/NEJMoa2114663.

Article  CAS  PubMed  Google Scholar 

Lloyd A. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95:683–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31:1001–10. https://www.annalsofoncology.org/article/S0923-7534(20)39798-2/fulltext.

Basu A, Ganiats TG. Discounting in cost-effectiveness analysis. In: Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, editors. Cost-Eff health med. Oxford University Press; 2016. p. 0. https://doi.org/10.1093/acprof:oso/9780190492939.003.0010.

Centers for Medicare & Medicaid Services. Physician fee schedule [Internet]. 2023 [cited 2024 Mar 9]. https://www.cms.gov/medicare/physician-fee-schedule/search

Bramley T, Antao V, Lunacsek O, Hennenfent K, Masaquel A. The economic burden of end-of-life care in metastatic breast cancer. J Med Econ. 2016;19:1075–80. https://doi.org/10.1080/13696998.2016.1197130.

Article  PubMed  Google Scholar 

Vemer P, Corro Ramos I, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. PharmacoEconomics. 2016;34(4):349–61. https://doi.org/10.1007/s40273-015-0327-2.

Kim J-Y, Shin J, Ahn JS, Park YH, Im Y-H. Real world experience of second-line treatment strategies after Palbociclib and Letrozole: overall survival in metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer. Cancers. 2023;15:3431. https://www.mdpi.com/2072-6694/15/13/3431.

USC Schaeffer. A Strategy for value-based drug pricing under the inflation reduction act [Internet]. 2023 [cited 2024 Jun 26]. https://healthpolicy.usc.edu/article/a-strategy-for-value-based-drug-pricing-under-the-inflation-reduction-act/.

Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274:113–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

American Cancer Society. Key Statistics for Breast Cancer [Internet]. 2024 [cited 2024 Jun 12]. https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html

Drugs.com. Faslodex Prices, Coupons, Copay & Patient Assistance [Internet]. 2024 [cited 2024 Jun 12]. https://www.drugs.com/price-guide/faslodex.

Drugs.com. Aromasin Prices, Coupons, Copay & Patient Assistance [Internet]. 2024 [cited 2024 Jun 12]. https://www.drugs.com/price-guide/aromasin.

Drugs.com. Everolimus Prices, Coupons, Copay & Patient Assistance [Internet]. 2024 [cited 2024 Jun 12]. https://www.drugs.com/price-guide/everolimus.

Drugs.com. Ibrance Prices, Coupons, Copay & Patient Assistance [Internet]. 2024 [cited 2024 Jun 12]. https://www.drugs.com/price-guide/ibrance.

Drug.com. Zoladex prices, coupons, copay and patient assistance [Internet]. [cited 2024 Jun 12]. https://www.drugs.com/price-guide/zoladex.